Qureight Series B raises $20 million for clinical trial imaging AI

Qureight Series B funding has reached $20 million, with Molten Ventures leading the round for the clinical trial imaging company. The financing gives the lung and heart disease-focused startup more capital to expand AI-based imaging tools used in drug development, though Qureight did not disclose its valuation, revenue, headcount or customer names.

Existing backers Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension also joined the round. Qureight said the raise brings its total funding to more than €27 million. The company describes itself as an end-to-end imaging provider for clinical trials, offering imaging operations, precision endpoints and analytics for biopharma studies.

The round is a conventional growth financing for a specialist clinical infrastructure startup, rather than a broad consumer AI play. It also shows where some venture capital is still willing to underwrite AI: regulated workflows where data handling, measurement and trial execution can be tied to specific budgets.

What is Qureight using the Series B for?

Qureight said it will use the new capital to build out an AI imaging laboratory around its 3D chest imaging foundation model. According to the company, that model is intended to cut both the amount of data and the development time needed to create disease-specific imaging models.

The company plans to extend its products into asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity. Those areas would add to Qureight’s existing work in lung fibrosis, where it says its services are already being used by biopharma partners to support clinical trials in fibrotic lung diseases.

Qureight’s platform includes imaging contract research organization services for handling trial images, onboarding clinical sites and helping with patient inclusion decisions. It also offers proprietary AI lung image biomarkers that the company says can measure structural changes linked to disease progression during a trial.

A third part of the product set is data science tooling, including synthetic control arms. In clinical trials, synthetic control arms use external or modeled patient data as a comparison group against an active study arm. Qureight says this can reduce trial cost and duration, but the company did not provide figures showing the size of those savings.

Who invested in Qureight?

Molten Ventures led the Series B. Qureight said Molten partner Dr. Inga Deakin will join its board of directors as part of the financing. Anna Salim of Hargreave Hale is also joining the board, according to the company.

Dr. Muhunthan Thillai, Qureight’s co-founder and chief executive, said the financing would help the company expand its 3D imaging deep learning models through the new AI laboratory and enter additional disease markets. He also framed the round as support for Qureight’s enterprise-grade imaging platform and team.

Deakin said Qureight shows how AI backed by real-world data can speed discovery and clinical research. That is the investor case. The operating test is narrower: whether Qureight can turn disease-specific imaging models into repeatable trial infrastructure for sponsors that need better endpoints, faster site workflows and regulatory-compliant evidence packages.

This story draws on original reporting from Tech.eu.